Norman "Ned" Sharpless, acting commissioner of the Food and Drug Administration, led the agency's first public hearing on CBD products May 31, and raised many questions regarding the safety of the ingredients, according to The Washington Post.
More than 100 stakeholders testified at the hearing, and while they differed in what they believed the regulations should be, they stressed that regulation decisions were urgent, as CBD use has become common.
Written comments on the issue are due July 2, and may be submitted here. Deputy Commissioner Amy Abernathy is leading a group that will research the legal and public health nature of CBD sales.
